Next Phase Newsletter

A leading European venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing therapeutic treatments to patients, with a focus on indications with high unmet needs. The firm has a diverse international team in Spain that is driven by science, with the ambition to transform capital into medical breakthroughs. The firm has over €400M million in assets under management through its three funds. The investments typically range from 5 million to 20 million, including additional capital for follow-on investments.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new family office fund of a successful hedge fund manager focused on private investments has multiple offices in the US. Due to the single LP structure of the fund, it can be very flexible in terms of investment size and stage. The firm is open to working with companies in the seed, series A, and series B stage with the majority of investments falling in the $500k-2.5M range. The firm also has the ability to allocate $5M or more in situations where they find the opportunity particularly compelling. The firm is capable of both acting as a lead and co-investor, and is primarily focused on companies throughout North America but has exposure to Europe and Asia as well.

The firm has a focus on vertically integrated platforms and software/”software x hardware” systems. Specifically, the firm is interested in AI-enabled drug discovery platforms, lab automation, diagnostics and data collection, and clinical trials management software. The firm is generally agnostic in terms of both stage of development and indication area but is most interested in early stage, highly innovative biotech companies.

The firm is looking for privately held companies with experienced management teams and a product/service with a large addressable market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Frazier Healthcare Ventures was founded in 1991 and is based in Seattle, WA.  The firm has $2.2 billion of assets under management, and closed a new $525 million fund in 2016.  Frazier currently has two investment strategies; growth-stage investments in healthcare and pharma service providers (these investments focus on companies with $5-30m EBITDA), and venture-stage investments in life science companies.  Frazier’s venture allocations have initial sizes of $5m or higher, with the potential for allocations of up to $20m over the life of an investment.  While Frazier primarily invests in companies based in or with significant operations in the USA and/or Canada, the firm will also consider opportunities in Europe.  In addition to growth and venture-stage investments, Frazier also engages in company creation.  The firm is a lead investor in most of its deals.

Frazier Life Sciences only invests in therapeutics, with a focus on asset-based companies. Frazier typically prefers to invest in companies with products which are 6-18 months away from bringing a product candidate into Phase I clinical trials, but may consider investing in assets that are earlier or later than that. The firm invests in all therapeutic areas and all modalities.

Frazier Healthcare Ventures has no fixed requirements for companies or management teams, but looks for strong teams that lead companies that can make use of over $10m in capital; companies with smaller capital needs are not of interest. Frazier can invest in both privately-held and public life science companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established, early-stage venture fund backed by a sole strategic LP and managed by leading VC firms is actively seeking new investment opportunities. The LP’s decision to invest in the fund reflects the company’s vision of developing disruptive, cost-saving healthcare solutions, which closely matches the vision of the investment team. The firm focuses on US, Europe, and Israel-based companies.

The firm is dedicated to early-stage investing in novel, disruptive medtech and digital health companies that can transform hospital care to lower-cost settings such as the home and health clinics. Areas of particular interest include non-invasive therapeutic medical devices, monitoring technologies for effective chronic disease management and preventative technologies, and is open to devices of all regulatory pathways.

The firm is looking for technologies supported by strong clinical hypotheses that can cost-effectively address large problems in the current healthcare system. The firm is open to working with all kinds of management teams in the US, Europe or Israel. The firm has access to an international network and resources that can be leveraged to support company growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital firm based in the US is focused on early and growth-stage biotech and pharma companies. The firm has more than $350M assets under management. Initial investments typically range from $2M-$20M and are usually in the form of equity, but may use convertible notes in select situations. The firm looks to take a meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.

The firm focuses on therapeutic companies within the biotech sector. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies developing assets with unique mechanisms of action that address unmet medical needs. The firm typically invests in companies ranging from late preclinical to Phase 2 clinical trials stage. The firm does NOT invest in diagnostic, device, digital health, or healthcare IT companies.

The firm has no strict company or management team requirements, but usually requires a board seat along with an investment to allow for active participation and collaboration with the company during development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused Growth Equity firm currently manages $1 billion and provides $20-100 million of equity capital per company over the life of the investment. With offices in the US and UK, the firm is primarily looking for companies throughout North America and Europe.

The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.

The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based multi-family office invests across several sectors, with a focus on life science and healthcare. The firm typically seek opportunities in Seed to Series A rounds, with an initial check size ranging from $500K to $3M USD. Within life science and healthcare, approximately half the firm’s investments have been in companies related to oncology, which is an area of special interest to the firm. While most of their investments have been in the US, the firm will consider opportunities in other countries like Canada and Europe. The firm is typically a co-investor.

Within life science and healthcare, the firm is interested in biotech therapeutics, medtech, and is open to diagnostics and life science tools as well. The firm is agnostic to subsectors, although cell and gene therapy is one area of interest. The firm is open to considering companies at an early stage of development, from pre-clinical to phase I for therapeutics and from in-development to clinical stage for medical devices. The firm is open to devices across all classes. For indications, oncology stands out as a particular area of interest for the firm.

While the firm does not have special requirements regarding the founding or management team. The firm does place emphasis on partnering with experienced founders and value the expertise and track record of the founder.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.